Skip to content

Goodwill at other companies

Abbott logo
AbbottABT
$35.22B+50.8%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$21.74B0.0%
Tenet Healthcare logo
Tenet HealthcareTHC
$11.39B+5.6%
Pfizer logo
PfizerPFE
$71.41B+4.3%
Procter & Gamble logo
Procter & GamblePG
$41.36B+2.2%
Merck & Co. logo
Merck & Co.MRK
$21.58B-0.5%

Segments

By segment

See full
MEDTECH$33.75B+0.6%
Innovative Medicine$14.81B+35.8%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's goodwill?
Johnson & Johnson (JNJ) reported goodwill of $48.56B in Q1 2026.
How has Johnson & Johnson's goodwill changed year-over-year?
Johnson & Johnson's goodwill increased by 9.2% year-over-year, from $44.47B to $48.56B.
What is the long-term trend for Johnson & Johnson's goodwill?
Over 5 years (2020 to 2025), Johnson & Johnson's goodwill has grown at a 6.0% compound annual growth rate (CAGR), from $36.39B to $48.77B.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.